Narvaez Javier, Domingo-Domenech Eva, Narvaez José A, Nolla Joan M, Valverde José
Department of Rheumatology, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.
Joint Bone Spine. 2005 Oct;72(5):424-6. doi: 10.1016/j.jbspin.2004.10.012. Epub 2005 Jan 26.
Hypophosphatemic osteomalacia is a rare but important complication of multiple myeloma. In these cases, the pathophysiology of the phosphate renal wasting notably differs from oncogenic osteomalacia and is due to light-chain nephropathy, resulting in proximal tubular dysfunction which is not restricted to phosphate handling. These patients seems to have a distinct type of plasma cell disorder characterized by a slow progression of the tumor and by an early phase dominated by the metabolic complications of the renal proximal tubular dysfunction. For this reason hypophosphatemic osteomalacia is the presenting feature that leads to the diagnosis of multiple myeloma in most of these patients. Recognition of this complication is important, since supportive treatment with phosphate supplements and calcitriol may substantially alleviate pain and weakness associated with hypophosphatemia.
低磷性骨软化症是多发性骨髓瘤一种罕见但重要的并发症。在这些病例中,肾脏磷酸盐流失的病理生理学与肿瘤性骨软化症显著不同,是由轻链肾病所致,导致近端肾小管功能障碍,且不仅限于磷酸盐处理。这些患者似乎有一种独特类型的浆细胞疾病,其特征为肿瘤进展缓慢以及早期以近端肾小管功能障碍的代谢并发症为主。因此,低磷性骨软化症是导致大多数此类患者诊断为多发性骨髓瘤的首发特征。认识到这种并发症很重要,因为补充磷酸盐和骨化三醇的支持性治疗可显著减轻与低磷血症相关的疼痛和虚弱。